Shining Cells Responsible for Developing Tumors Discovered

A new specific marker for cancer stem cells: riboflavin, or vitamin B2, a pigment that emits green fluorescence as a result of its accumulation inside intracellular vesicles has been discovered by Spanish National Cancer Research Centre researchers.

Results from the research, headed by scientists Irene Miranda, Bruno Sainz and Christopher Heeschen, are published today in the journal Nature Methods.

About Cancer in Women
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.

"The discovery of this new marker is a breakthrough, as it can select for tumour stem cells, which are the most invasive and chemical-resistant cancer cells. Autofluorescence allows these cells to be tracked in an easy, simple and inexpensive way, as well as to study the origin of the tumours' chemical resistance," states Irene Miranda, the article's first author.

"Normally, we only see the leaves of the tree represented by tumours, but we cannot make out the roots [the cancer stem cells], which are the true responsible parties for the progression and growth of tumours," illustrates Miranda.

Cells shining, thanks to a vitamin

Lifetime Risk Calculator for Cancers
What are your chances for developing some common cancers in your lifetime - find out now.
The discovery −which was carried out in several types of tumours, including samples from patients with pancreas, liver, colon and lung cancer− raises a question: why do tumour stem cells accumulate vitamin B2?

In the article, researchers show that this is due to an increase in ABCG2, the protein responsible for the transport of vitamin B2 into intracellular vesicles, conferring luminosity to the cells. The factors behind this phenomenon are yet to be determined.

Quiz on Pancreatic Cancer
Pancreatic cancer is often diagnosed at a late stage and can be fatal. Test your knowledge on pancreatic cancer by taking this quiz.

Despite unknowns regarding its nature, autofluorescence could help to launch future approaches in personalised medicine and to develop more effective anticancer treatments. "We will now be able to isolate autofluorescent cells from a biopsy and to test their sensitivity in a panel of experimental or marketed drugs," affirm Sainz and Heeschen. "In this way, we want to accelerate the identification of new drugs or their use in combination, in order to specifically destroy the patient´s cancer stem cells," says Sainz.
Source-Eurekalert

Standard Care for HER2-Positive Breast Cancer: Trastuzumab
Trastuzumab, Herceptin, should remain the standard of care for HER2-positive breast cancer, says a Mayo Clinic researcher, after analysis of more than 8,000 women with the cancer.